Ross Maclean

2.0k total citations
38 papers, 1.6k citations indexed

About

Ross Maclean is a scholar working on Rheumatology, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Ross Maclean has authored 38 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Rheumatology, 9 papers in Hematology and 7 papers in Pathology and Forensic Medicine. Recurrent topics in Ross Maclean's work include Rheumatoid Arthritis Research and Therapies (19 papers), Autoimmune and Inflammatory Disorders Research (7 papers) and Lymphoma Diagnosis and Treatment (6 papers). Ross Maclean is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (19 papers), Autoimmune and Inflammatory Disorders Research (7 papers) and Lymphoma Diagnosis and Treatment (6 papers). Ross Maclean collaborates with scholars based in United States, Germany and Canada. Ross Maclean's co-authors include Wayne N. Burton, Alan Morrison, Eric Ruderman, Lara Maxwell, Peter Tugwell, Theodore Pincus, Yusuf Yazıcı, Ron Z. Goetzel, Ronald J. Ozminkowski and Martin Bergman and has published in prestigious journals such as Blood, Journal of the American Society of Nephrology and Annals of the Rheumatic Diseases.

In The Last Decade

Ross Maclean

38 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ross Maclean United States	20	811	397	282	255	194	38	1.6k
Annette de Thurah Denmark	24	882 1.1×	420 1.1×	124 0.4×	240 0.9×	232 1.2×	99	1.8k
Thomas Mittendorf Germany	23	441 0.5×	160 0.4×	465 1.6×	248 1.0×	99 0.5×	105	1.7k
D Whalley United Kingdom	14	878 1.1×	367 0.9×	302 1.1×	288 1.1×	273 1.4×	27	2.0k
Andrew Hassell United Kingdom	30	1.0k 1.3×	352 0.9×	81 0.3×	293 1.1×	173 0.9×	87	2.2k
Fowzia Ibrahim United Kingdom	28	807 1.0×	385 1.0×	83 0.3×	159 0.6×	237 1.2×	97	2.4k
Estíbaliz Loza Spain	29	1.3k 1.6×	366 0.9×	136 0.5×	134 0.5×	276 1.4×	154	2.4k
Jennifer L. Barton United States	22	817 1.0×	302 0.8×	83 0.3×	325 1.3×	243 1.3×	60	1.5k
Jonathan Tosh United Kingdom	17	311 0.4×	192 0.5×	540 1.9×	243 1.0×	141 0.7×	41	1.3k
Zulma Ortiz Argentina	15	286 0.4×	146 0.4×	128 0.5×	184 0.7×	201 1.0×	35	1.6k
Ingris Peláez‐Ballestas Mexico	22	834 1.0×	397 1.0×	60 0.2×	169 0.7×	94 0.5×	153	1.7k

Countries citing papers authored by Ross Maclean

Since Specialization

Citations

This map shows the geographic impact of Ross Maclean's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ross Maclean with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ross Maclean more than expected).

Fields of papers citing papers by Ross Maclean

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ross Maclean. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ross Maclean. The network helps show where Ross Maclean may publish in the future.

Co-authorship network of co-authors of Ross Maclean

This figure shows the co-authorship network connecting the top 25 collaborators of Ross Maclean. A scholar is included among the top collaborators of Ross Maclean based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ross Maclean. Ross Maclean is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gibson, Teresa B., et al.. (2015). Value-based insurance design: benefits beyond cost and utilization.. PubMed. 21(1). 32–5. 11 indexed citations

Pincus, Theodore, P. Hines, Martin Bergman, et al.. (2011). Proposed Severity and Response Criteria for Routine Assessment of Patient Index Data (RAPID3): Results for Categories of Disease Activity and Response Criteria in Abatacept Clinical Trials. The Journal of Rheumatology. 38(12). 2565–2571. 30 indexed citations

Katz, Patricia, Diane C. Radvanski, Diane D. Allen, et al.. (2011). Development and validation of a short form of the valued life activities disability questionnaire for rheumatoid arthritis. Arthritis Care & Research. 63(12). 1664–1671. 25 indexed citations

Johnston, Stephen S., Suellen M. Curkendall, Dinara Makenbaeva, et al.. (2010). The Direct and Indirect Cost Burden of AcuteCoronary Syndrome. Journal of Occupational and Environmental Medicine. 53(1). 2–7. 41 indexed citations

Yuan, Yong, et al.. (2009). Indirect cost-effectiveness analyses of abatacept and rituximab in patients with moderate-to-severe rheumatoid arthritis in the United States. Journal of Medical Economics. 13(1). 33–41. 19 indexed citations

Kim, Edward, et al.. (2009). Time to psychiatric hospitalization in patients with bipolar disorder treated with a mood stabilizer and adjunctive atypical antipsychotics: A retrospective claims database analysis. Clinical Therapeutics. 31(4). 836–848. 14 indexed citations

Gibson, Teresa B., Eliza Ng, Ronald J. Ozminkowski, et al.. (2008). The Direct and Indirect Cost Burden of Crohn's Disease and Ulcerative Colitis. Journal of Occupational and Environmental Medicine. 50(11). 1261–1272. 145 indexed citations

Cole, Jason C., T. Li, Phoebe Lin, Ross Maclean, & Gene V. Wallenstein. (2008). Treatment impact on estimated medical expenditure and job loss likelihood in rheumatoid arthritis: re-examining quality of life outcomes from a randomized placebo-controlled clinical trial with abatacept. Lara D. Veeken. 47(7). 1044–1050. 14 indexed citations

Pincus, Theodore, Yusuf Yazıcı, Martin Bergman, Ross Maclean, & Timothy Harrington. (2007). A proposed continuous quality improvement approach to assessment and management of patients with rheumatoid arthritis without formal joint counts, based on quantitative routine assessment of patient index data (RAPID) scores on a multidimensional health assessment questionnaire (MDHAQ). Best Practice & Research Clinical Rheumatology. 21(4). 789–804. 45 indexed citations

10.

Martin, Marie C., Mark Kosinski, Jakob Bue Bjørner, et al.. (2007). Item Response Theory Methods can Improve the Measurement of Physical Function by Combining the Modified Health Assessment Questionnaire and the SF-36 Physical Function Scale. Quality of Life Research. 16(4). 647–60. 45 indexed citations

11.

Wells, George, et al.. (2007). Responsiveness of patient reported outcomes including fatigue, sleep quality, activity limitation, and quality of life following treatment with abatacept for rheumatoid arthritis. Annals of the Rheumatic Diseases. 67(2). 260–265. 123 indexed citations

12.

Vera‐Llonch, Montserrat, Elena Massarotti, Frederick Wolfe, et al.. (2007). Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate. Lara D. Veeken. 47(4). 535–541. 37 indexed citations

13.

Pincus, Theodore, Martin Bergman, Yusuf Yazıcı, et al.. (2007). An index of only patient-reported outcome measures, routine assessment of patient index data 3 (RAPID3), in two abatacept clinical trials: similar results to disease activity score (DAS28) and other RAPID indices that include physician-reported measures. Lara D. Veeken. 47(3). 345–349. 117 indexed citations

14.

Snyder, Jon J., Bertram L. Kasiske, & Ross Maclean. (2006). Peripheral Arterial Disease and Renal Transplantation. Journal of the American Society of Nephrology. 17(7). 2056–2068. 58 indexed citations

15.

Ozminkowski, Ronald J., Wayne N. Burton, Ron Z. Goetzel, Ross Maclean, & Shaohung Wang. (2006). The Impact of Rheumatoid Arthritis on Medical Expenditures, Absenteeism, and Short-Term Disability Benefits. Journal of Occupational and Environmental Medicine. 48(2). 135–148. 69 indexed citations

16.

Russell, Anthony S., Gene V. Wallenstein, Michael C. Martin, et al.. (2006). Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment. Annals of the Rheumatic Diseases. 66(2). 189–194. 57 indexed citations

17.

Burton, Wayne N., Alan Morrison, Ross Maclean, & Eric Ruderman. (2005). Systematic review of studies of productivity loss due to rheumatoid arthritis. Occupational Medicine. 56(1). 18–27. 227 indexed citations

18.

Devineni, Trishul, et al.. (2004). A Pilot Study of Feasibility and Efficacy of Telemedicine-Delivered Psychophysiological Treatment for Vascular Headache. Telemedicine Journal and e-Health. 10(4). 449–454. 5 indexed citations

19.

Kotzan, Jeffrey A., et al.. (2002). Prevalence and patterns of concomitant use of selective serotonin reuptake inhibitors and other antidepressants in a high-cost polypharmacy cohort. Clinical Therapeutics. 24(2). 237–248. 14 indexed citations

20.

Maclean, Ross, et al.. (2002). Inpatient mortality: a reflection of quality care?. PubMed. 6(4). 169–73. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact